Tempus AI (TEM): Assessing Valuation Following Analyst Optimism on Growth Drivers and Precision Medicine Collaboration

Simply Wall St.11-29

Tempus AI (TEM) is drawing new attention after analysts highlighted strong momentum from its Ambry acquisition, advances in rare disease testing, and a new collaboration focused on precision medicine....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2587676555?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2025-11-29 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2587676555","market":"hk","top_or_hot":-1,"title":"Tempus AI (TEM): Assessing Valuation Following Analyst Optimism on Growth Drivers and Precision Medicine Collaboration","media":"Simply Wall St.","content":"<div>\n<p>Tempus AI (TEM) is drawing new attention after analysts highlighted strong momentum from its Ambry acquisition, advances in rare disease testing, and a new collaboration focused on precision medicine....</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-assessing-valuation-following-analyst-optimism\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI (TEM): Assessing Valuation Following Analyst Optimism on Growth Drivers and Precision Medicine Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI (TEM): Assessing Valuation Following Analyst Optimism on Growth Drivers and Precision Medicine Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-29 20:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-assessing-valuation-following-analyst-optimism><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tempus AI (TEM) is drawing new attention after analysts highlighted strong momentum from its Ambry acquisition, advances in rare disease testing, and a new collaboration focused on precision medicine....</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-assessing-valuation-following-analyst-optimism\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4528","symbol_name":"SaaS概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-assessing-valuation-following-analyst-optimism","article_id":"2587676555","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-assessing-valuation-following-analyst-optimism","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2587676555","pubTimestamp":1764418996,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Tempus AI (TEM) is drawing new attention after analysts highlighted strong momentum from its Ambry acquisition, advances in rare disease testing, and a new collaboration focused on precision medicine. Investors are watching closely as these factors develop.\nSee our latest analysis for Tempus AI.\nTempus AI’s share price has surged more than 127% year to date as interest in healthcare innovation grows, even with some volatility along the way. Recent momentum from its Ambry acquisition and new...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4528":"SaaS概念","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4588":"碎股","BK4023":"应用软件","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4585":"ETF&股票定投概念","BK4613":"AI应用软件","TEM.AU":"TEMPEST MINERALS LTD","BK4611":"AI医疗","BK4121":"生命科学工具和服务","BK4543":"AI","TEM":"Tempus AI","BK4587":"ChatGPT概念","BK7095":"多种金属与采矿","BK4551":"寇图资本持仓","AI":"C3.ai, Inc."},"translate_title":"Tempus AI(TEM)：在分析师对增长动力和精准医疗合作持乐观态度后评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AI":0.9,"TEM.AU":1.5,"TEM":1.5},"content_text":"Tempus AI (TEM) is drawing new attention after analysts highlighted strong momentum from its Ambry acquisition, advances in rare disease testing, and a new collaboration focused on precision medicine. Investors are watching closely as these factors develop. See our latest analysis for Tempus AI. Tempus AI’s share price has surged more than 127% year to date as interest in healthcare innovation grows, even with some volatility along the way. Recent momentum from its Ambry acquisition and new precision medicine partnerships suggests investors see further room for long-term growth. If you’re curious about what other healthcare innovators are capturing attention, it’s a great moment to discover See the full list for free. Given these new catalysts and robust growth drivers, the central question becomes whether Tempus AI’s current share price still presents a buying opportunity, or if the market is already pricing in the company’s anticipated growth ahead. AdvertisementMost Popular Narrative: 14.4% Undervalued Tempus AI’s latest fair value estimate stands at $91 per share, significantly higher than the most recent closing price of $77.93. This prominent narrative suggests that the market may not have fully reflected all anticipated growth drivers and potential profitability improvements in its current valuation.   Robust discipline in investment and operating leverage, as evidenced by rapid revenue growth paired with improving adjusted EBITDA and gross margins, supports near-term profitability and strengthens the case for long-term scalable earnings expansion. Secular increases in the adoption of AI and data analytics in drug development, along with broadening regulatory clarity for digital diagnostics, indicate that Tempus AI is uniquely positioned to capture a growing share of healthcare spending. This is expected to directly increase revenue and enhance future opportunities for margin improvement.\n    Read the complete narrative. Can a wave of AI-driven margins and long-term revenue acceleration justify this notable valuation? The narrative revolves around whether meaningful improvements in profit and growth will reshape its financial outlook. Want to see the specifics fueling the analysts’ optimism? Unlock the detailed forecasts that support these figures. Result: Fair Value of $91 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, intensifying competition and looming reimbursement uncertainties could still test the durability of Tempus AI’s growth narrative in the coming years. Find out about the key risks to this Tempus AI narrative. Another View: What Do Multiples Say? While some models point to Tempus AI being undervalued, a closer look at its price-to-sales ratio tells a different story. At 12.5x, it is significantly higher than both the industry average of 3.7x and the peer average of 5.5x, as well as the fair ratio of 9.3x. This raises the possibility that investors have already priced in plenty of optimism, leaving less room for upside based on fundamentals. Could this high valuation signal a riskier entry point? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:TEM PS Ratio as at Nov 2025 Build Your Own Tempus AI Narrative If you want to dig into the numbers and shape your own perspective, it's easy to build a custom narrative in just a few minutes. Do it your way A great starting point for your Tempus AI research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. Looking for more smart stock ideas? Unlock your investment potential by exploring powerful opportunities you might be missing. Take the next step and discover what is ahead in top growth sectors.  Capitalize on market growth by checking out these 920 undervalued stocks based on cash flows that stand out based on strong cash flow fundamentals. Position yourself at the forefront of technology with these 25 AI penny stocks that are reshaping everything from automation to cloud computing. Secure steady returns with these 15 dividend stocks with yields > 3% offering yields above 3% for investors who value both growth and income.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tempus AI might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2587676555","isCrawlerRequest":true}